Aptose Biosciences (APTO) Rating Lowered to Hold at Zacks Investment Research
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
Several other research analysts have also recently weighed in on APTO. HC Wainwright set a $9.00 price target on shares of Aptose Biosciences and gave the stock a “buy” rating in a report on Monday, November 26th. Roth Capital reaffirmed a “buy” rating on shares of Aptose Biosciences in a report on Wednesday, December 12th. Oppenheimer started coverage on shares of Aptose Biosciences in a report on Thursday, January 24th. They issued an “outperform” rating and a $6.00 price target on the stock. Citigroup started coverage on shares of Aptose Biosciences in a report on Friday, January 25th. They issued an “outperform” rating and a $6.00 price target on the stock. Finally, Royal Bank of Canada started coverage on shares of Aptose Biosciences in a report on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target on the stock. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $5.75.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). On average, research analysts expect that Aptose Biosciences will post -0.72 EPS for the current year.
In related news, Director Erich Platzer sold 20,000 shares of the company’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $2.19, for a total value of $43,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Gregory K. Chow bought 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was bought at an average price of $1.75 per share, with a total value of $26,250.00. Following the completion of the transaction, the chief financial officer now directly owns 122,014 shares of the company’s stock, valued at approximately $213,524.50. The disclosure for this purchase can be found here.
Large investors have recently made changes to their positions in the stock. Noven Financial Group Inc. purchased a new position in Aptose Biosciences in the fourth quarter worth $27,000. Geode Capital Management LLC purchased a new position in Aptose Biosciences in the fourth quarter worth $33,000. Patriot Financial Group Insurance Agency LLC grew its position in Aptose Biosciences by 11.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 5,890 shares in the last quarter. Citadel Advisors LLC purchased a new position in Aptose Biosciences in the third quarter worth $125,000. Finally, Renaissance Technologies LLC grew its position in Aptose Biosciences by 1,130.9% in the third quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock worth $477,000 after acquiring an additional 168,501 shares in the last quarter. Institutional investors own 7.88% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More: Stock Symbol
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.